Back to Directory

Grace Montepiedra

Email

gmontepie@sdac.harvard.edu

Phone

617-432-1141

Institution

Statistical and Data Analysis Center

Title

Research Scientist

Address

Statistical and Data Analysis Center
Pediatric Neurology and Adolescent Sections
Harvard School of Public Health
FXB Building, Room 517
651 Huntington Avenue
Boston, MA 02115-6017
United States of America

Request an Update

Affiliated Studies

IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

38754

Research Area

Tuberculosis

Study Status

Enrolling

IMPAACT 2001: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection

DAIDS Number

12026

Research Area

Tuberculosis

Study Status

Participants Off Study and Primary Analysis Completed

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) Given in Combination with an Individualized Rifampin-Resistant Tuberculosis (RR-TB) Therapy in Infants, Children and Adolescents with RR-TB Disease, Living with or without HIV

DAIDS Number

11884

Research Area

Tuberculosis

Study Status

Closed to Accrual

P1042S: Cognitive, Behavioral, and Psychosocial Correlates of Medication Adherence

DAIDS Number

10107

Research Area

Other

Study Status

Concluded

IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Two to Less Than 13 Years of Age with and without HIV

DAIDS Number

38747

Research Area

Tuberculosis

Study Status

In Development

Show All